{"organizations": [], "uuid": "e363e7d99ae35306786780e54b4b11ba0c2abb7a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-iterum-therapeutics-says-expects-i/brief-iterum-therapeutics-says-expects-initial-public-offering-price-to-be-between-14-and-16-per-share-idUSFWN1SN0S2", "country": "US", "domain_rank": 408, "title": "BRIEF-Iterum Therapeutics Says Expects Initial Public Offering Price To Be Between $14 And $16 Per Share", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.213, "site_type": "news", "published": "2018-05-16T20:46:00.000+03:00", "replies_count": 0, "uuid": "e363e7d99ae35306786780e54b4b11ba0c2abb7a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-iterum-therapeutics-says-expects-i/brief-iterum-therapeutics-says-expects-initial-public-offering-price-to-be-between-14-and-16-per-share-idUSFWN1SN0S2", "ord_in_thread": 0, "title": "BRIEF-Iterum Therapeutics Says Expects Initial Public Offering Price To Be Between $14 And $16 Per Share", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sec", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "iterum therapeutics plc", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "erum therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) -\n* ITERUM THERAPEUTICS PLC SEES IPO OF 5,333,333 ORDINARY SHARES - SEC FILING\n* ITERUM THERAPEUTICS SAYS EXPECTS INITIAL PUBLIC OFFERING PRICE TO BE BETWEEN $14.00 AND $16.00 PER SHARE\n* ITERUM THERAPEUTICS - INTENDS TO USE ABOUT $65 MILLION OF IPO PROCEEDS TO FUND PHASE 3 CLINICAL TRIALS OF ORAL SULOPENEM, SULOPENEM IN THREE INDICATIONS\n* ITERUM THERAPEUTICS - INTENDS TO USE ABOUT $15 MILLION OF IPO PROCEEDS FOR MILESTONE PAYMENTS TO PFIZER INC Source text: [ bit.ly/2rMAthB ]\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://bit.ly/2rMAthB", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T20:46:00.000+03:00", "crawled": "2018-05-17T14:24:04.002+03:00", "highlightTitle": ""}